Veranex, the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
Formed in partnership with global growth investor Summit Partners, the company provides the global medical technology industry integrated product development strategies and services across the product life cycle. As a result of this transaction, Veranex’s West Coast operations offer a unique, client-responsive consulting model that adjusts to meet client program requirements.
“We are excited to welcome Experien Group to Veranex,” said David Dockhorn, CEO of Veranex. “With this acquisition, Veranex adds the premier provider of regulatory, quality, and clinical consulting services to medtech companies. Veranex’s clients will benefit from Experien’s long-standing FDA engagement, well-established global regulatory guidance experience, and a demonstrated track record of successful approvals.”
“Experien Group adds another layer of value and medtech insight to Veranex,” said Veranex Executive Chairman Pat Donnelly. “We will continue to seek additional strategic acquisitions that add depth and resources to the full-service, end-to-end medtech solutions that Veranex has brought to the industry for the first time.”
Veranex combines product development, regulatory, and market access expertise — globally and across complex and emerging markets — to help clients achieve their innovation objectives, accelerating time to market and optimizing clinical adoption and patient access.
Financial terms of the transaction were not disclosed.